Skip to main content
. 2022 Jan 17;12:784489. doi: 10.3389/fphar.2021.784489

FIGURE 3.

FIGURE 3

miR-671-5p aggravates β-catenin-induced podocyte injury while miR-671-5p inhibitor ameliorates it in vitro. (A–C) Representative Western blot (A) and graphic presentations of WT1 (B) and podocalyxin (C) were presented. MPC5 cells were transfected with miR-671-5p mimics (miR-671-5p) or/and β-catenin expression plasmid (pDel-β-cat) for 24 h *p < 0.05 versus pcDNA3 controls; †p < 0.05 versus pDel-β-cat (n = 3). (D–H) Representative Western blot (D) and graphic presentations of podocalyxin (E), nephrin (F), ZO-1 (G) and WT1 (H) were presented. MPC5 cells were transfected with β-catenin expression plasmid (pDel-β-cat) or/and miR-671-5p inhibitor (AntimiR-671-5p) for 24 h *p < 0.05 (n = 3). (I) Representative micrographs show the expression of ZO-1 in different groups as indicated. MPC5 cells were transfected with β-catenin expression plasmid (pDel-β-cat) and miR-671-5p mimics (miR-671-5p)/miR-671-5p inhibitor (AntimiR-671-5p) for 24 h, respectively. Scale bar, 50 µm.